These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 34305008)

  • 1. Accommodating clinical trials and other externally manufactured cellular therapy products: challenges, lessons learned and creative solutions.
    Jackson MR
    Cytotherapy; 2022 Jan; 24(1):37-44. PubMed ID: 34305008
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Paving the Road for Chimeric Antigen Receptor T Cells: American Society for Transplantation and Cellular Therapy 80/20 Task Force Consensus on Challenges and Solutions to Improving Efficiency of Clinical Center Certification and Maintenance of Operations for Commercially Approved Immune Effector Cell Therapies.
    Nikiforow S; Frigault MJ; Frey NV; Gardner RA; Komanduri KV; Perales MA; Kebriaei P; Warkentin PI; Pasquini M; Aho JL; Levine BL; Heslop HE; Hlucky TL; Habucky K; Gharibo M; Jagasia M; Locke FL
    Transplant Cell Ther; 2023 Apr; 29(4):228-239. PubMed ID: 36709800
    [TBL] [Abstract][Full Text] [Related]  

  • 3. How the COVID-19 pandemic changed cellular therapy at Columbia University Irving Medical Center/NewYork-Presbyterian Hospital.
    Tanhehco YC; Schwartz J
    Transfusion; 2020 Sep; 60(9):1905-1909. PubMed ID: 32583465
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Healthcare center-based cell therapy laboratories supporting off-site manufactured cell therapies: The experiences of a single academic cell therapy laboratory.
    Dinh A; Stroncek DF
    Transfusion; 2024 Feb; 64(2):357-366. PubMed ID: 38173340
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of contracted manufacturing organization protocols on operations in an aca demically based Current Good Manufacturing Practice facility.
    Sutherland V; Buffo MJ; Whiteside TL
    Cytotherapy; 2022 Jan; 24(1):32-36. PubMed ID: 33610480
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amotosalen: Allogeneic Cellular Immunotherapies system, INTERCEPT Plasma System, INTERCEPT Platelet System, S 59.
    BioDrugs; 2003; 17(1):66-8. PubMed ID: 12534321
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of externally manufactured cell therapy products: the Mayo Clinic approach.
    Wiltshire TD; Deeds MC; Radel DJ; Bornschlegl AM; Schmidt CS; Thebiay JM; Pelleymounter LL; Jacob EK; Stubbs JR; Gastineau DA; Dietz AB
    Cytotherapy; 2022 Jan; 24(1):19-26. PubMed ID: 34980364
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expanding the reach of commercial cell therapies requires changes at medical centers.
    Stroncek DF; Zhang N; Ren J; Somerville R; Dinh A
    J Transl Med; 2024 Feb; 22(1):181. PubMed ID: 38374090
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Establishment of a cell processing laboratory to support hematopoietic stem cell transplantation and chimeric antigen receptor (CAR)-T cell therapy.
    Mukherjee S; Reddy O; Panch S; Stroncek D
    Transfus Apher Sci; 2021 Feb; 60(1):103066. PubMed ID: 33472742
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Variations in novel cellular therapy products manufacturing.
    Fontaine MJ; Selogie E; Stroncek D; McKenna D; Szczepiorkowski ZM; Takanashi M; Garritsen H; Girdlestone J; Reems JA;
    Cytotherapy; 2020 Jun; 22(6):337-342. PubMed ID: 32223996
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The quest for quality blood banking program in the new millennium the American way.
    Kim DU
    Int J Hematol; 2002 Aug; 76 Suppl 2():258-62. PubMed ID: 12430934
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Establishing a Satellite Transfusion Service Within an Academic Medical Center.
    Murphy CH; Lim AY; Chua L; Shan H; Goodnough LT; Virk MS
    Am J Clin Pathol; 2020 May; 153(6):842-849. PubMed ID: 32157269
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Raising the standard: changes to the Australian Code of Good Manufacturing Practice (cGMP) for human blood and blood components, human tissues and human cellular therapy products.
    Wright C; Velickovic Z; Brown R; Larsen S; Macpherson JL; Gibson J; Rasko JE
    Pathology; 2014 Apr; 46(3):177-83. PubMed ID: 24614714
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Minnesota Molecular and Cellular Therapeutics Facility: a state-of-the-art biotherapeutics engineering laboratory.
    McKenna DH; Kadidlo DM; Miller JS; Orchard PJ; Wagner JE; McCullough J
    Transfus Med Rev; 2005 Jul; 19(3):217-28. PubMed ID: 16010652
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cellular Therapies Clinical Research Roadmap: lessons learned on how to move a cellular therapy into a clinical trial.
    Ouseph S; Tappitake D; Armant M; Wesselschmidt R; Derecho I; Draxler R; Wood D; Centanni JM
    Cytotherapy; 2015 Apr; 17(4):339-43. PubMed ID: 25484311
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Voluntary accreditation of cellular therapies: Foundation for the Accreditation of Cellular Therapy (FACT).
    Warkentin PI;
    Cytotherapy; 2003; 5(4):299-305. PubMed ID: 12944235
    [TBL] [Abstract][Full Text] [Related]  

  • 18. How do we… direct a transfusion service/blood bank with limited laboratory staff.
    Lu W; Bakhtary S; Oliver L; Stephens L; Tanhehco Y; O'Brien K
    Transfusion; 2023 Nov; 63(11):2023-2031. PubMed ID: 37642158
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The NCI All Ireland Cancer Conference.
    Johnston PG; Daly PA; Liu E
    Oncologist; 1999; 4(4):275-277. PubMed ID: 10545862
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Six Sigma: not for the faint of heart.
    Benedetto AR
    Radiol Manage; 2003; 25(2):40-53. PubMed ID: 12800564
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.